STX-478

Eli Lilly is set to acquire Scorpion Therapeutics' PI3Kα inhibitor program, including STX-478, currently in Phase I/II trials, for up to $2.5 billion.

Allosteric PIK3CA inhibitors, like STX-478 and RLY-2608, offer a more targeted approach with improved safety profiles compared to orthosteric inhibitors.

STX-478, a novel allosteric, mutant-selective PI3Kα inhibitor, demonstrates clinical activity and tolerability in patients with advanced solid tumors.

STX-478 is an orally available, CNS-penetrant allosteric inhibitor designed to selectively target mutant PI3Kα, a key player in various cancers.

STX-478, an oral PI3Kα inhibitor, demonstrated anti-tumor activity in a Phase 1/2 trial, with an overall response rate of 23% in breast cancer patients.